A carregar...
Publicação
TG4010 immunotherapy: a novel weapon against advanced non-small cell lung cancer?
Autores
Orientador(es)
Resumo(s)
Over 1.5 million new cases of non-small cell lung cancer
(NSCLC), a highly aggressive disease, are registered
worldwide every year (1). Until the 1980s, treatment
generally yielded poor outcomes (2), and prognosis was
only good for early stages of operable disease. However,
advances in targeted molecular therapy since 2005 have
brought new hope to patients with advanced NSCLC,
especially those harboring the epidermal growth factor receptor
(EGFR) mutation in exons 18, 19 and 21 (3). As a result, the
median overall survival (OS) of a small group of patients with
advanced NSCLC increased from 10 to 18–36 months (2).